Key clinical point: Pembrolizumab consolidation after autologous stem cell transplant (ASCT) did not meet its primary survival endpoint for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Major finding: The 18-month progression-free survival was 58%, which failed to meet the pre-specified primary outcome (60%-80% improvement in progression-free survival at 18 months).
Study details: A phase 2, single-arm trial of 29 patients with relapsed/refractory DLBCL.
Disclosures: The study was funded by Merck. The authors reported financial disclosures related to Merck and several other companies.
Frigault MJ et al. Blood Adv. 2020 Jan 14. doi: 10.1182/bloodadvances.2019000784.